The partnership will launch with a pilot program beginning in April of this year wherein certain patients whose risk for relapse is continuously measured by MAP's patient engagement technology will be issued a Soberlink breathalyzer that links to the patient's MAP profile. The device, which utilizes facial recognition technology, will send real-time data to MAP's care platform when a patient performs a test with negative results, misses scheduled tests, or tests positive for alcohol use. With this information, MAP's technology will inform the appropriate members of collaborative care teams if a patient is at an elevated risk for relapse or has returned to alcohol use. Ultimately, this data is leveraged to improve clinical outcomes and manage financial risk through facilitating early interventions and other means of mitigating recidivism and costly treatment episodes.
— Jacob Levenson, CEO of MAP Health Management
— Brad Keays, CEO of Soberlink